@article{9590770ea0f649c38d66efc75f5dfeab,
title = "HIV and the Liver",
abstract = "Among individuals with HIV infection, liver disease remains an important cause of morbidity and mortality, even with the availability of agents that cure hepatitis C infection and suppress hepatitis B replication. The causes of liver disease are multifaceted and continue to evolve as the population ages and new etiologies arise. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis and hepatitis viruses such as A, D, and E have emerged even as hepatitis C has receded. Newer antiretroviral agents may increase risk of weight gain and subsequent fatty infiltration, and prior use of nucleotide-based therapies may continue to impact liver health. Several barriers including economics, social stigma, and psychiatric disease impact identification of liver disease, as well as management and treatment interventions. Hepatocellular carcinoma is emerging as a more common and late-diagnosed complication in those with HIV infection and liver disease.",
keywords = "ART, HIV, NAFLD, NASH, antiretroviral therapy, hepatitis, hepatocellular carcinoma, liver",
author = "Sherman, {Kenneth E.} and Peters, {Marion G.} and Thomas, {David L.}",
note = "Funding Information: Funding for this conference was made possible [in part] by the National Institutes of Health under Award Number 2R13AI071925-08. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. Also supported in part by educational grants from: Abbott Diagnostics, Dova Pharmaceuticals, Gilead Sciences, Inc., Janssen Therapeutics, LP, Salix, and ViiV Healthcare. Funding Information: The National Institutes of Health under Award Number 2R13AI071925-08. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. Also supported in part by educational grants from: Abbott Diagnostics, Dova Pharmaceuticals, Gilead Sciences, Inc., Janssen Therapeutics, LP, Salix, and ViiV Healthcare. Publisher Copyright: {\textcopyright} 2019, IAS-USA. All rights reserved.",
year = "2019",
month = sep,
language = "English (US)",
volume = "27",
pages = "101--110",
journal = "Topics in Antiviral Medicine",
issn = "2161-5861",
publisher = "International Antiviral Society",
number = "3",
}